Latest news with #MohitBansal
Yahoo
19-06-2025
- Business
- Yahoo
Regeneron Pharmaceuticals, Inc. (REGN) Growth Story Shifts as Wells Fargo Maintains Hold
On June 10, 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a 'Hold' rating from Wells Fargo, which set the company's stock price target at $580. REGN is one of the 7 52-week low dividend stocks to consider Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biotechnology company, develops treatments in ophthalmology, oncology, and immunology. Wells Fargo's analyst, Mohit Bansal, cited the early resubmission of the Eylea HD pre-filled syringe for FDA review, pointing toward its limited financial impact on the company. While the analyst did indicate some incremental revenue growth potential through the drug, she believes that it will get neutralized. This is evident in Eylea's Q1 2025 performance, where U.S. sales of its older 2 mg formula fell 39%, while the newer, higher dose saw a 54% growth. A close up photograph of a vial of a new biotechnological drug candidate in development. The analyst further highlighted the company's shifting growth narrative as Eylea no longer remains central to the company's growth strategy. As such, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is shifting its focus to its broader pipeline. Although the company's Dupixent global sales saw a YoY increase of 20% and Libtayo posted decent returns, regulatory delays continue to weigh on investor sentiment. Thus, analysts remain cautious, with short-term headwinds countering long-term pipeline optimism. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-06-2025
- Business
- Yahoo
PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
Wells Fargo analyst Mohit Bansal notes that PTAB has instituted Merck's (MRK) patent grant review against Halozyme Therapeutics (HALO) MDASE patents. This patent is one of the patents Merck is fighting against Halozyme. The firm believes this likely reduces the probability of Halozyme prevailing in this case and weakens the bull argument. Wells has an Equal Weight on Halozyme with a price target of $65 on the shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on HALO: Disclaimer & DisclosureReport an Issue Merck granted review of Halozyme patent claims by PTAB Halozyme's Strategic Positioning and Market Potential Drive Buy Rating Halozyme announces EC approval of Bristol Myers' Opdivo developed with Enhanze Optimistic Buy Rating for Halozyme Amid Price Control Concerns Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley
Yahoo
31-01-2025
- Business
- Yahoo
No Major Catalyst, Wells Fargo Downgraded Vertex
January 31, 2025 Wells Fargo analyst Mohit Bansal was not excited by the upcoming launches of Vertex Pharmaceutical (NASDAQ:VRTX)'s drugs, Alyftrek and Suzetrigine. So, the analyst downgraded Vertex from Overweight to Equal-Weight and lowering the target price to $460, which was reached today. Bansal saw no major catalyst could drive the stock up in the near future, he also mentioned that Vertex might need to add more pipelines to its drug portfolio to drive growth. Warning! GuruFocus has detected 5 Warning Signs with VRTX. According to the consensus that consist of 29 analysts, the target price for Vertex is ranged from $325.00 to $591.00 with the average of $495.25. GuruFocus estimates the value for Vertex is $434.37, suggesting a downside from current price of $460.64. This article first appeared on GuruFocus. Sign in to access your portfolio
